Relevance of fecal calprotectin as a biomarker to predict the outcome of Adalimumab therapy in Ulcerative Colitis patients.
Not Applicable
- Conditions
- lcerative Colitis
- Registration Number
- JPRN-UMIN000022104
- Lead Sponsor
- Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnant woman *Patients who become pregnant during study period to be required to discontinue the study 2. Patients unable to provide informed consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method